Breaking News

Endo Appoints Corporate Development VP

April 29, 2014

Valeant veteran brings specialty pharma experience

Hemanth J. Varghese, Ph.D., CFA, has been appointed executive vice president of corporate development and strategy at Endo International. Dr. Robert Cobuzzi, who previously served in this role will now serve as senior vice president, U.S. branded pharmaceuticals R&D strategy and operations. Dr. Varghese will report to Rajiv De Silva, Endo's president and chief executive officer.
Dr. Varghese brings corporate development and general management experience in specialty pharmaceuticals, most recently serving as senior vice president and general manager vision care for Bausch & Lomb, a division of Valeant Pharmaceuticals. Dr. Varghese also held senior leadership roles at Valeant, including senior vice president of corporate development and general manager of Valeant's Neurology & Other business unit.
"We are excited to announce the addition of Hemanth to the Endo executive team. His accomplishments and experience in corporate development and integrations will allow us to accelerate the execution of our strategy as we continue to expand our business through value creating acquisitions and partnerships," said Mr. De Silva. "Hemanth's track record of success will play a significant role as we execute against our strategy to become a leading specialty healthcare company."

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important